At Takeda, we are currently experiencing low inventory of Vyvanse capsules due to a manufacturing delay compounded by increased demand. Recognizing this delay could impact your patients’ ability to fill prescriptions for Vyvanse capsules, we have mobilized appropriate resources to replenish our supply as quickly as possible.
This delay has temporarily impacted our ability to distribute this product to wholesalers who supply retail pharmacies. We anticipate that this delay will affect the 40mg, 60mg, and 70mg dosage strengths. Supply of the 40mg strength will dip in mid-June and will be replenished in a few weeks. The impact to the 60mg and 70mg strengths is expected to begin in late June or early July and continue into September. It is possible that an increased demand on other dosage strengths of Vyvanse may occur, resulting in localized shortages of these other strengths. If this supply situation affects your patients, you may need to consider other therapeutic options for your patients.
We are updating the U.S. Food and Drug Administration (FDA) about this temporary supply delay and will continue to provide updates if necessary.
We understand that you may need to consider potential treatment alternatives for any Vyvanse patient impacted by this supply chain delay, which might include prescribing a combination of other dosage strengths of Vyvanse to maintain the patient's daily dosage treatment plan. If you determine that this is the best choice for your patient, please note that Takeda has temporarily adjusted its co-pay assistance program so that, where permitted by law, the majority of those commercially insured or cash-paying patients who are currently enrolled in the Vyvanse savings card program do not experience increased Vyvanse prescription co-payment amounts.* All other terms and conditions of the co-pay assistance program would continue to apply. Information on the Vyvanse co-pay assistance/savings card program can be found here. In the event that alternative dosing combinations place an increased demand on other dosage strengths of Vyvanse, you may need to consider other therapeutic options for your patients currently taking Vyvanse.
We regret the potential disruption in your patients' care that this may cause and appreciate your understanding while we collaborate with our suppliers to deliver additional supply as quickly as possible.
If you have additional questions or concerns regarding this issue, please call Takeda Medical Information at 1-877-TAKEDA-7 (1-877-825-3327).
*Each patient’s insurance coverage may be different and can impact the patient’s co-pay when filling their prescription for Vyvanse. Some patients may experience an increase in their co-pay amount when filling their Vyvanse prescription with a combination of dosage strengths.